Source:http://linkedlifedata.com/resource/pubmed/id/14526879
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2003-10-6
|
pubmed:abstractText |
Oral fungal infections frequently develop in individuals with advanced cancer. This study examined the oral mycological flora of 207 patients receiving palliative care for advanced malignant disease. Demographic details and a clinical history were documented from each participant. A tongue swab was collected and cultured on CHROMAgar Candida (CHROMAgar Paris, France). All yeasts were identified by germ tube test, API ID 32C profiles and, for Candida dubliniensis, by species-specific PCR. Susceptibility to fluconazole and itraconazole was determined by a broth microdilution assay according to the National Committee for Clinical Laboratory Standards (NCCLS). At time of sampling, 54 (26%) of the 207 subjects had clinical evidence of a fungal infection and yeasts were isolated from 139 (67%) individuals. In total, 194 yeasts were isolated, of which 95 (49%) were Candida albicans. There was a high prevalence of Candidia glabrata (47 isolates) of which 34 (72%) were resistant to both fluconazole and itraconazole. All nine isolates of C. dubliniensis recovered were susceptible to both azoles. No relationship was established between anti-fungal usage in the preceding three months and the presence of azole resistant yeasts. This study of patients with advanced cancer has demonstrated a high incidence of oral colonization with non-C. albicans yeasts, many of which had reduced susceptibility to fluconazole and itraconazole. The role of improved oral care regimes and novel anti-fungal drugs merits further attention, to reduce the occurrence of fungal infection in these patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0269-2163
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
477-81
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:14526879-Adult,
pubmed-meshheading:14526879-Aged,
pubmed-meshheading:14526879-Aged, 80 and over,
pubmed-meshheading:14526879-Antifungal Agents,
pubmed-meshheading:14526879-Drug Resistance, Fungal,
pubmed-meshheading:14526879-Female,
pubmed-meshheading:14526879-Fluconazole,
pubmed-meshheading:14526879-Humans,
pubmed-meshheading:14526879-Itraconazole,
pubmed-meshheading:14526879-Male,
pubmed-meshheading:14526879-Middle Aged,
pubmed-meshheading:14526879-Mouth,
pubmed-meshheading:14526879-Mouth Diseases,
pubmed-meshheading:14526879-Mycoses,
pubmed-meshheading:14526879-Neoplasms,
pubmed-meshheading:14526879-Opportunistic Infections,
pubmed-meshheading:14526879-Palliative Care,
pubmed-meshheading:14526879-Yeasts
|
pubmed:year |
2003
|
pubmed:articleTitle |
High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer.
|
pubmed:affiliation |
Glasgow Dental Hospital and School, University of Glasgow, Glasgow, UK. j.bagg@dental.gla.ac.uk
|
pubmed:publicationType |
Journal Article
|